|
Article Excerpt
QUEBEC CITY, QC, Canada, Dec. 15 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a growing global biopharmaceutical company focused on endocrine therapy and oncology, announced today that its shareholders approved its proposed reduction in stated capital and the special distribution in kind of the remaining 11,052,996 subordinate voting shares of the capital of Atrium Biotechnologies Inc. (TSX: ATB) held by AEterna Zentaris at the special meeting of shareholders this morning. In addition, for informational purposes only, 99.57% of all proxies received, representing a total of 30,151,201 common shares, were in favor of the special distribution.
Following...
|
|
More articles from PR Newswire
John M. Boushy Elected to Ameristar Board., December 15, 2006
Wavefront Energy & Environmental Services Inc. Letter of Intent to acq..., December 15, 2006
Infinity Completes Sale of Oilfield Service Subsidiaries for $52 Milli..., December 15, 2006
Lionsgate's Acclaimed Showtime Comedy WEEDS Earns Four Golden Globe Aw..., December 15, 2006
Brookdale Increases Fourth Quarter Common Stock Dividend to $0.45., December 15, 2006
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
